<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0121-7577</journal-id>
<journal-title><![CDATA[Hacia la Promoción de la Salud]]></journal-title>
<abbrev-journal-title><![CDATA[Hacia promoc. Salud]]></abbrev-journal-title>
<issn>0121-7577</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Caldas. Vicerrectoría de Investigaciones y Postgrados]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0121-75772017000200129</article-id>
<article-id pub-id-type="doi">10.17151/hpsal.2017.22.2.10</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[ESTRATEGIAS LATINOAMERICANAS PARA LA VACUNACIÓN CONTRA EL VIRUS DEL PAPILOMA HUMANO - UNA REVISIÓN TEMÁTICA]]></article-title>
<article-title xml:lang="en"><![CDATA[LATIN AMERICAN STRATEGIES FOR VACCINATION AGAINST HUMAN PAPILLOMAVIRUS INFECTION - A THEMATIC REVIEW]]></article-title>
<article-title xml:lang="pt"><![CDATA[ESTRATEGIAS LATINOAMERICANAS PARA A VACINAÇÃO CONTRA O VIRUS DO PAPILOMA HUMANO - UMA REVISÃO TEMÁTICA]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Salazar-Fajardo]]></surname>
<given-names><![CDATA[Lida Janneth]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Benavides-Delgado]]></surname>
<given-names><![CDATA[Mónica Rocío]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Boogaard]]></surname>
<given-names><![CDATA[Sabine]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Marín]]></surname>
<given-names><![CDATA[Yolanda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Cancerología  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Nacional de Cancerología  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Nacional de Cancerología  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Instituto Nacional de Cancerología  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<volume>22</volume>
<numero>2</numero>
<fpage>129</fpage>
<lpage>143</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0121-75772017000200129&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0121-75772017000200129&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0121-75772017000200129&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo:  Conocer las estrategias para asumir la vacunación contra el virus del papiloma humano en América Latina a partir de una revisión temática internacional, para encontrar experiencias que contribuyan a mantener resultados satisfactorios en Colombia.  Materiales y métodos:  Se realizó una revisión de literatura internacional en español, inglés y portugués sobre el estado de implementación y éxito del programa de vacunación en América Latina en bases de datos: Medline, Embase y Cochrane, portales de Organización Mundial y Panamericana de la Salud, páginas web de entes rectores y sitios electrónicos especializados en control del cáncer.  Resultados:  Se revisaron 97 referencias. En la región, diez países incorporaron dosis de la vacuna en sus esquemas para niñas entre 9 y 13 años; realizan diversas estrategias a corto plazo para mantener sus tasas de cobertura; siendo la articulación de los sectores salud-educación, el reconocimiento del contexto y la obligatoriedad las más exitosas.  Conclusión:  La situación en otros países en la implementación de la vacunación contra el VPH, muestra que la alianza entre salud, educación y comunicación es clave para mantener resultados satisfactorios. Educar y sensibilizar puede mantener la articulación con la comunidad. La aceptación o rechazo de la vacunación, depende del grado de información de la población; por tanto, es útil la consulta con profesionales de la salud y la aplicación de consentimiento informado para reducir la incertidumbre.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective:  To know the strategies to take responsibility for vaccination against human papillomavirus infection in Latin America through an international thematic review to find experiences that contribute to maintain satisfactory results in Colombia.  Materials and methods:  A review of international literature in Spanish, English and Portuguese about the state of implementation and achievement of the vaccination programs used in Latin America was carried out using the Medline, Embase and Cochrane Library electronic databases, portals of the World Health Organization and Pan American Health Organization, governmental websites, and websites specialized in cancer control.  Results:  Ninety-seven references were reviewed. Ten countries in the region incorporated the vaccine doses in their program among 9 and 13 years old girls. They perform several short-term strategies to maintain their coverage rates, being the articulation between the health-education sectors, the context recognition, and their obligatory nature the most successful.  Conclusion:  The situation in other countries regarding the implementation of an HPV-vaccination program shows that the alliance between healthcare, education and communication is the key to the sustainability of satisfactory results. Educating and raising awareness can maintain the articulation with the community. The acceptance or rejection of the vaccine depends on the degree of information of the population. Therefore, consultation with health-professionals and the application of informed consent are useful to reduce uncertainty.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Objetivo:  Com as estratégias para assumir a vacinação contra o vírus do papiloma humano em América Latina a partir de uma revisão temática internacional, para encontrar experiências que contribuíam a manter resultados satisfatórios em Colômbia.  Materiais e métodos:  Realizou se uma revisão de literatura internacional em espanhol, inglês e português sobre o estado de implementação e êxito do programa de vacinação em América Latina em bases de dados: Medline, Embase e Cochrane, portais de Organização Mundial e Panamericana da Saúde, páginas web de entes reitores e sites eletrônicos especializados em controle do câncer.  Resultados:  Conferiram se 97 referencias. Na região, dez países incluem dosagem da vacina em seus esquemas para meninas entre 9 e 13 anos; realizam diversas estratégias a corto prazo para manter suas taxas de cobertura; sendo a articulação dos setores saúde- educação, o reconhecimento do contexto e a obrigatoriedade com mais sucesso.  Conclusão:  As situações em outros países incluíram a vacinação contra o VPH, amostra que a união entre saúde, educação e comunicação é clave para manter resultados satisfatórios. Educar e sensibilizar pode manter a articulação com a comunidade. A aceitação o rejeição da vacinação, depende do grau de informação da povoação; por tanto, é útil a consulta com profissionais da saúde e a aplicação de consentimento informado para reduzir a incerteza.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Vacuna]]></kwd>
<kwd lng="es"><![CDATA[VPH]]></kwd>
<kwd lng="es"><![CDATA[política pública]]></kwd>
<kwd lng="es"><![CDATA[salud pública]]></kwd>
<kwd lng="es"><![CDATA[implementación]]></kwd>
<kwd lng="en"><![CDATA[Vaccine]]></kwd>
<kwd lng="en"><![CDATA[HPV]]></kwd>
<kwd lng="en"><![CDATA[public politics]]></kwd>
<kwd lng="en"><![CDATA[public health]]></kwd>
<kwd lng="en"><![CDATA[implementation]]></kwd>
<kwd lng="pt"><![CDATA[Vacina]]></kwd>
<kwd lng="pt"><![CDATA[VPH]]></kwd>
<kwd lng="pt"><![CDATA[política pública]]></kwd>
<kwd lng="pt"><![CDATA[saúde pública]]></kwd>
<kwd lng="pt"><![CDATA[inclusão]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>International Agency for Research on Cancer (IARC)</collab>
<source><![CDATA[IARC Monographs on the Evaluation of Carcinogenic Risks to Humans]]></source>
<year>2007</year>
<page-range>90</page-range><publisher-loc><![CDATA[Lyon ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burchell]]></surname>
<given-names><![CDATA[AN]]></given-names>
</name>
<name>
<surname><![CDATA[Winer]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[De Sanjose]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Franco]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chapter 6: Epidemiology and transmission dynamics of genital VPH infection]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2006</year>
<volume>24</volume>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>S52-61</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferlay]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Soerjomataram]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ervik]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dikshit]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Eser]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mathers]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rebelo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Parkin]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Forman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bray]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide]]></source>
<year>2013</year>
<publisher-name><![CDATA[IARC]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<collab>Centers for Disease Control and Prevention (CDC)</collab>
<source><![CDATA[Recommended adult immunization schedule: United States, 2010]]></source>
<year>2010</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stillo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Carrillo Santisteve]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lopalco]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Safety of human papillomavirus vaccines: a review. Expert Opinion on Drug Safety]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Committee opinion no. 467: human papillomavirus vaccination]]></article-title>
<source><![CDATA[Obstet Gynecol]]></source>
<year>2010</year>
<volume>116</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>800-3</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saslow]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Castle]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cox]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Davey]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Einstein]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ferris]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[American Cancer Society Guideline for human papillomavirus (VPH) vaccine use to prevent cervical cancer and its precursors]]></article-title>
<source><![CDATA[CA Cancer J Clin]]></source>
<year>2007</year>
<volume>57</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>7-28</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<collab>Organización Mundial de la Salud (OMS)</collab>
<article-title xml:lang=""><![CDATA[Meeting of the WHO Human Papillomavirus Vaccine Advisory Committee, April 2010]]></article-title>
<source><![CDATA[Wkly Epidemiol Rec]]></source>
<year>2011</year>
<volume>86</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>227-31</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<collab>Organización Panamericana de la Salud (OPS)</collab>
<source><![CDATA[OMS/OPS resalta la importancia de la vacuna contra el VPH en Colombia]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<collab>Ministerio de Salud y de la Protección Social. Gobierno de Colombia</collab>
<source><![CDATA[Colombia cuenta con las mejores coberturas de vacunación contra el VPH en el mundo]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brotherton]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Deeks]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Campbell-Lloyd]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Misrachi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Passaris]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Peterson]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia]]></article-title>
<source><![CDATA[Commun Dis Intell Q Rep]]></source>
<year>2008</year>
<volume>32</volume>
<page-range>457-61</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Forero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caso de niñas del Carmen de Bolívar desplomó vacunación contra el VPH]]></article-title>
<source><![CDATA[El Tiempo]]></source>
<year>2015</year>
<month>,</month>
<publisher-loc><![CDATA[Colombia ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gervas Camacho]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Segura Benedicto]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[García-Onieva]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Ética y vacunas: más allá del acto clínico]]></source>
<year>2010</year>
<page-range>229-36</page-range><publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Sociedad de Pediatría de Madrid y Castilla]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villa]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biology of genital human papillomaviruses]]></article-title>
<source><![CDATA[International Journal of Gynecology and Obstetrics]]></source>
<year>2006</year>
<volume>94</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S3-7</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<collab>Food and Drug Administration (FDA)</collab>
<source><![CDATA[Highlights of prescribing information (Cervarix)]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="">
<collab>Cervical Cancer.org</collab>
<source><![CDATA[Global Progress in VPH Vaccination]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="">
<collab>European Medicines Agency (EMA)</collab>
<source><![CDATA[Gardasil human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed)]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[David]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Van Herck]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hardt]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term persistence of anti-VPH-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>2009</year>
<volume>115</volume>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>S1-6</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vaccine risks: real, perceived and unknown]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>1999</year>
<volume>17</volume>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>S41-6</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vichnin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bonanni]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Klein]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Garland]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Block]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kjaer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An Overview of Quadrivalent Human Papillomavirus Vaccine Safety 2006 to 2015]]></article-title>
<source><![CDATA[The Pediatric Infectious Disease Journal]]></source>
<year>2015</year>
<volume>34</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>983-91</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arnheim-Dahlström]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pasternak]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Svanström]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Sparén]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hviid]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: Cohort study]]></article-title>
<source><![CDATA[British Medical Journal]]></source>
<year>2013</year>
<volume>347</volume>
<page-range>f5906</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="">
<collab>The American College of Obstetricians and Gynecologists</collab>
<source><![CDATA[Committee opinion. Human Papillomavirus Vaccination]]></source>
<year>2015</year>
<page-range>641</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="">
<collab>WHO Global Advisory Committee on Vaccine Safety Statement on the continued safety of HPV vaccination</collab>
<source><![CDATA[Extract from report of GACVS meeting of 11-12 December 2013]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Petaja]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Pedersen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Poder]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Strauss]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Catteau]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term persistence of systemic and mucosal immune response to VPH-16/18 AS04-adjuvanted vaccine in preteen/ adolescent girls and young women]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2011</year>
<volume>129</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2147-57</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Basu]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Banerjee]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ch]]></surname>
<given-names><![CDATA[Bhattacharya]]></given-names>
</name>
<name>
<surname><![CDATA[Biswas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of human papillomavirus vaccine for primary prevention of cervical cancer: a review of evidence from phase III trials and national programs]]></article-title>
<source><![CDATA[South Asian J Cancer]]></source>
<year>2013</year>
<volume>2</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>187-92</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="">
<collab>Instituto Nacional del Cáncer de los Institutos Nacionales de la Salud de EE. UU</collab>
<source><![CDATA[Vacunas contra el Virus del Papiloma Humano]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="">
<collab>Ministerio de Sanidad, Servicios Sociales e Igualdad de España. Gobierno de España</collab>
<source><![CDATA[Coberturas de vacunación frente a VPH pauta completa niñas de 11 a 14 años]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="">
<collab>Consensus Statement</collab>
<source><![CDATA[NCI-designated Cancer Centers Urge HPV Vaccination for the Prevention of Cancer]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="">
<collab>Organización Mundial de la Salud (OMS)</collab>
<source><![CDATA[Coberturas de vacunación contra el VPH]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shefer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Markowitz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Deeks]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tam]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Irwin]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Garland]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early experience with human papillomavirus vaccine introduction in the United States, Canada and Australia]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2008</year>
<volume>26</volume>
<numero>^s10</numero>
<issue>^s10</issue>
<supplement>10</supplement>
<page-range>K68-75</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garland]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Brotherton]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Skinner]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Pitts]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Saville]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mola]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Human papillomavirus and cervical cancer in Australasia and Oceania: risk-factors, epidemiology and prevention]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2008</year>
<volume>26</volume>
<numero>^s12</numero>
<issue>^s12</issue>
<supplement>12</supplement>
<page-range>M80-8</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baseman]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Koutsky]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The epidemiology of human papillomavirus infections]]></article-title>
<source><![CDATA[J Clin Virol]]></source>
<year>2005</year>
<volume>32</volume>
<page-range>16-24</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sankaranarayanan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bhatla]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Gravitt]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Basu]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Esmy]]></surname>
<given-names><![CDATA[PO]]></given-names>
</name>
<name>
<surname><![CDATA[Ashrafunnessa]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka and Nepal]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2008</year>
<volume>26</volume>
<numero>^s12</numero>
<issue>^s12</issue>
<supplement>12</supplement>
<page-range>M43-52</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Sanjose]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Diaz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Castellsague]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Clifford]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bruni]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Munoz]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bosch]]></surname>
<given-names><![CDATA[FX]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis]]></article-title>
<source><![CDATA[Lancet Infect Dis]]></source>
<year>2007</year>
<volume>7</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>453-9</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Manalastas Jr]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pitisuttithum]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Tresukosol]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Monsonego]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ault]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2009</year>
<volume>373</volume>
<numero>9679</numero>
<issue>9679</issue>
<page-range>1949-57</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pedersen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Petaja]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Strauss]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rumke]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Poder]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Richardus]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HPV Vaccine Adolescent Study Investigators Network. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant]]></article-title>
<source><![CDATA[J Adolesc Health]]></source>
<year>2007</year>
<volume>40</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>564-71</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Skinner]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Garland]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Stanley]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pitts]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Quinn]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Human papillomavirus vaccination for the prevention of cervical neoplasia: is it appropriate to vaccinate women older than 26?]]></article-title>
<source><![CDATA[Med J Aust]]></source>
<year>2008</year>
<volume>188</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>238-42</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Block]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Nolan]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sattler]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Barr]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Giacoletti]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Marchant]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Protocol 016 Study Group. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women]]></article-title>
<source><![CDATA[Pediatrics]]></source>
<year>2006</year>
<volume>118</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>2135-45</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fleider]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Estrategias para la Implementación de la Vacuna Profiláctica para la Infección por VPH en Argentina. Beca Interna de Investigación EGD Dr. César Ambrosio Tognoni]]></source>
<year>2010</year>
</nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="">
<collab>Fondo de las Naciones Unidas para la Infancia (UNICEF)</collab>
<source><![CDATA[Panamá, primer país de América Latina en ofrecer la vacuna contra el papiloma humano de forma gratuita]]></source>
<year>2008</year>
</nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="">
<collab>Organización de las Naciones Unidas (ONU)</collab>
<source><![CDATA[OPS consulta con expertos la relación entre el cáncer bucal y el virus del papiloma humano]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="">
<collab>Gobierno de la República de Honduras</collab>
<source><![CDATA[Salud introduce vacuna del Virus del Papiloma Humano (VPH) para niñas de 11 años en SPS]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="">
<collab>Organización Panamericana de la Salud (OPS)</collab>
<source><![CDATA[Ministerio de Salud introduce la vacuna contra el Virus del Papiloma Humano para prevenir el cáncer cérvico uterino]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="">
<collab>Secretaría de Salud de México</collab>
<source><![CDATA[Vacunas contra el Virus del papiloma Humano (VPH)]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="">
<collab>Ministerio de Salud Pública del Ecuador</collab>
<source><![CDATA[Vacuna contra el virus del papiloma humano previene cáncer uterino en el Ecuador]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="">
<collab>Ministerio de Salud de Chile</collab>
<source><![CDATA[Vacunación contra el virus del papiloma humano]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="">
<collab>Ministerio de Salud de la Nación de Argentina. Gobierno de Argentina</collab>
<source><![CDATA[Lineamientos Técnicos. Transición a vacuna cuadrivalente]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="">
<collab>Organización Mundial de la Salud (OMS)</collab>
<source><![CDATA[Documento de posición de la OMS sobre las vacunas contra el virus del papiloma humano (VPH)]]></source>
<year>2009</year>
</nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="">
<collab>Ministerio de Salud de Perú</collab>
<source><![CDATA[Resumen de una experiencia y evaluación del proyecto piloto de la vacuna contra el VPH en el Perú. Julio de 2009]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="">
<collab>Organización Panamericana de la Salud (OPS)</collab>
<source><![CDATA[MSP inició vacunación contra HPV en adolescentes para prevenir cáncer de cuello de útero]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="">
<collab>Portal da Saúde - Ministério da Saúde do Brasil</collab>
<source><![CDATA[É a primeira vez que a população terá acesso gratuito a uma vacina que protege contra câncer]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="">
<collab>Ministerio de Salud Pública y Bienestar Social, Dirección General de Vigilancia de la Salud y Programa Ampliado de Inmunizaciones</collab>
<source><![CDATA[Lineamientos Técnicos y Operativos para la vacunación contra el virus del papiloma humano (VPH)]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="">
<collab>Ministerio de Salud y de la Protección Social de Colombia. Gobierno de Colombia</collab>
<source><![CDATA[Colombia cuenta con las mejores coberturas de vacunación contra el VPH en el mundo]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="">
<collab>Instituto Nacional de Salud de Colombia (INS)</collab>
<source><![CDATA[Estudio de enfermedad supuestamente atribuible a la vacunación contra VPH]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="">
<collab>Centers for Disease Control and Prevention (CDC)</collab>
<source><![CDATA[Comunicado]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brotherton]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Human papillomavirus vaccination: Where are we now?]]></article-title>
<source><![CDATA[J Paediatr Child Health]]></source>
<year>2014</year>
<volume>50</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>959-65</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Binagwaho]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wagner]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gatera]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Karema]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Nutt]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ngabo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Cómo alcanzar una cobertura elevada en el programa nacional de vacunación contra el virus del papiloma humano en Rwanda]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="">
<collab>Union Internationale Contre le Cancer (UICC)</collab>
<source><![CDATA[Curriculum VPH y cáncer]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tay]]></surname>
<given-names><![CDATA[EH]]></given-names>
</name>
<name>
<surname><![CDATA[Garland]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Nolan]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Orloski]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical trial experience with prophylactic HPV 6/11/16/18 VLP vaccine in young women from the Asia-Pacific region]]></article-title>
<source><![CDATA[Int J Gynaecol Obstet]]></source>
<year>2008</year>
<volume>102</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>275-83</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
